{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:10:07Z","timestamp":1793315407254,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.03.032","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T02:03:07Z","timestamp":1490925787000},"page":"5951-5955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Alan D.T.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.032_b0005","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/S0140-6736(16)31838-4","article-title":"Fractional dosing of yellow fever vaccine to extend supply: a modelling study","volume":"388","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.032_b0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2017.03.032_b0015","series-title":"Vaccines","article-title":"Yellow fever vaccine","author":"Monath","year":"2013"},{"key":"10.1016\/j.vaccine.2017.03.032_b0020","doi-asserted-by":"crossref","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.03.032_b0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4269\/ajtmh.1928.s1-8.103","article-title":"Experimental transmission of yellow fever to laboratory animals","volume":"8","author":"Stokes","year":"1928","journal-title":"Am J Trop Med"},{"key":"10.1016\/j.vaccine.2017.03.032_b0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.03.032_b0035","unstructured":"World Health Organization. Standards for the Manufacture and Control of Yellow Fever Vaccine. World Health Organ Epidemiol Bull. Vol. 1. Geneva: World Health Organization; 1945. p. 365\u201370."},{"key":"10.1016\/j.vaccine.2017.03.032_b0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/0074-02760150176","article-title":"A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D\u2013213\/77 in children nine-23 months old","volume":"110","author":"Collaborative Group for Studies of Yellow Fever Vaccine","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2017.03.032_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.032_b0050","unstructured":"World Health organization; 2016. <www.who.int\/ith\/annex7-ihr.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2017.03.032_b0055","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.032_b0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","article-title":"Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial","volume":"72","author":"Pfister","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.032_b0065","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.032_b0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0168-1702(94)00076-O","article-title":"Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D\u2013213","volume":"35","author":"dos Santos","year":"1995","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.03.032_b0075","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1128\/JVI.79.13.8339-8347.2005","article-title":"Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains","volume":"79","author":"Beasley","year":"2005","journal-title":"J Virol"},{"issue":"suppl_5","key":"10.1016\/j.vaccine.2017.03.032_b0080","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1093\/cid\/civ603","article-title":"Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali","volume":"61","author":"Chowdhury","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.032_b0085","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/14760584.2015.1083430","article-title":"Current status and future prospects of yellow fever vaccines","author":"Beck","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.032_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond\u2013the problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.032_b0095","unstructured":"World Health Organization. <http:\/\/www.who.int\/topics\/international_health_regulations\/en\/>."},{"issue":"July","key":"10.1016\/j.vaccine.2017.03.032_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijid.2016.05.001","article-title":"Why is the yellow fever outbreak in Angola a 'threat to the entire world'?","volume":"48","author":"Woodall","year":"2016","journal-title":"Intl J Inf Dis"},{"key":"10.1016\/j.vaccine.2017.03.032_b0105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3201\/eid2210.160818","article-title":"Resurgence of yellow fever in Angola, 2015\u20132016","volume":"22","author":"Grobbelaar","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.032_b0110","unstructured":"World Health Organization. Yellow Fever Situation Report, 10.28.2016. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/250661\/1\/yellowfeversitrep28Oct16-eng.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2017.03.032_b0115","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(16)30620-1","article-title":"Yellow fever: the resurgence of a forgotten disease","volume":"387","author":"Chan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.032_b0120","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(16)30835-2","article-title":"Yellow fever continues to spread in Angola","volume":"387","author":"Green","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.032_b0125","unstructured":"World Health Organization. World Yellow Fever Situation Report, 05.08.2016. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/247198\/1\/yellowfeversitrep-5Aug2016-eng.pdf>."},{"key":"10.1016\/j.vaccine.2017.03.032_b0130","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.03.032_b0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline","volume":"14","author":"Campi-Azevedo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.032_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31330-7","article-title":"Modelling a way out of yellow fever","author":"Visser","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.032_b0145","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.032_b0150","unstructured":"World Health Organization. Global Strategy to Eliminate Yellow Fever Epidemics (EYE), 9.26.2016. <http:\/\/www.who.int\/immunization\/sage\/meetings\/2016\/october\/2_EYE_Strategy.pdf?ua=1>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:59:45Z","timestamp":1568980785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17303389"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}